Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13736023 | 0.82 | TSHR (0.52) | TSHRHPGDCYP1A2MAPTSMN1; SMN2 | |
| SCHEMBL31119746 | 0.81 | TSHR (0.43) | TSHRLMNAMEN1CYP1A2KMT2A | |
| SCHEMBL3179028 | 0.81 | CCNB2 (0.38) | TSHRLMNAHPGDMEN1KMT2A | |
| SCHEMBL4203638 | 0.79 | HSP90AB1 (0.40) | TSHRLMNAHPGDMEN1CYP1A2 | |
| SCHEMBL6029086 | 0.79 | PTGDR2 (0.44) | TSHRMEN1KMT2AFFAR1 | |
| SCHEMBL2549786 | 0.77 | KDM4E (0.57) | TSHRHPGDCXCR1CXCR2MAPT | |
| SCHEMBL31119667 | 0.77 | TSHR (0.47) | TSHRLMNAMEN1CYP1A2KMT2A | |
| SCHEMBL31119719 | 0.76 | PTGS2 (0.52) | TSHRMEN1CYP1A2KMT2APTGS2 | |
| SCHEMBL24259487 | 0.73 | TSHR (0.44) | TSHRLMNAHPGDMEN1CYP1A2 | |
| SCHEMBL14880635 | 0.73 | DGAT1 (0.43) | LMNAKMT2ASMN1; SMN2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358181-B1 | SUBSTITUTED PYRROLIDINES AS CCR-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| EP-1358181-A1 | SUBSTITUTED PYRROLIDINES AS CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| US-20030199532-A1 | 2,4-substituted pyrrolidine derivatives-CCR-3 receptor antagonists | KERTESZ DENIS JOHN (US) | 2003-10-23 | — | — | US | disclosed |
| US-6552028-B2 | Inhibiting the binding of eotaxin to chemokine-3 (ccr-3) receptor; antiasthmatics | SYNTEX (U.S.A.) LLC | 2003-04-22 | — | — | US | disclosed |
| US-20020198255-A1 | 2,4-substituted pyrrolidine derivatives-CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC | 2002-12-26 | — | — | US | disclosed |
| WO-2002050064-A1 | SUBSTITUTED PYRROLIDINES AS CCR-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199532-A1 | 2,4-substituted pyrrolidine derivatives-CCR-3 receptor antagonists | CCR3, CCR1, CCR4 | TSHR 1101/4885LMNA 4209/4885HPGD 1923/4885 |
| US-20020198255-A1 | 2,4-substituted pyrrolidine derivatives-CCR-3 receptor antagonists | CCR3, CCR1, CCR4 | TSHR 1101/4885LMNA 4209/4885HPGD 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.